Scholars Central

Conference abstractPublished 2016

Targeted delivery of generic chemotherapeutic agents to solid tumors via systemic nanotetrac (nanodiamino- tetrac)

Authors: Paul J Davis, Thangirala Sudha, Shaker A Mousa

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Covalently bound to a poly (lactic-co-glycolic acid) (PLGA) polymer via a linker, tetraiodothyroacetic acid (tetrac) as Nano-diamino-tetrac (NDAT) targets a specific cell surface receptor on the extracellular domain of integrin αvβ3. αvβ3 is primarily expressed by cancer cells and rapidly dividing endothelial cells relevant to tumors. Conjugation of tetrac and linker to a 120 nm PLGA nanoparticle limits cell entry of the compound and offers an opportunity to load the nanoparticle with a generic cancer chemotherapeutic agent for tumor-targeted delivery. Even without a payload, NDAT has anticancer and anti-angiogenesis properties. We established xenografts of human urinary bladder cancer (263JBV) cells and of human pancreatic cancer (SUIT-2) cells in nude mice and tumor growth and tumor content of cisplatin (263JBV xenografts) and of paclitaxel (SUIT-2 xenografts) were compared in multiple animal cohorts. These included: 1) untreated xenografted controls; 2) controls treated with void PLGA nanoparticles (NPs), 3) daily standard treatment with chemotherapeutic agent (cisplatin, 1 mg/kg, doxorubicin, 1 mg/kg or paclitaxel, 0.3 mg/kg), alone, 4) daily treatment with NDAT, alone, at a concentration with low anticancer activity, 5) daily treatment with chemotherapeutic agent encapsulated into PLGA NPs (no tetrac), and 6) daily treatment with chemotherapeutic agent loaded into NDAT. The dose of NDAT in groups 4 and 5 was 0.3 mg tetrac/kg. Daily drug treatments were continued for 3 weeks after establishment of xenografts in nude mice. Urinary bladder tumor weight at animal sacrifice decreased insignificantly vs. controls in animals that received cisplatin or cisplatin + PLGA. Submaximal dosing of NDAT, alone, induced a small, but significant, decreased in tumor weight. Tumors in animals treated with NDAT bearing a payload of cisplatin decreased in weight by 50% (P <0.01) and mean cisplatin content (LC/MS/MS) of tumors (ng/ gm of tissue) was 5-fold more than in animals treated with cisplatin, alone, and 3-fold more than in animals treated with PLGA NPs with encapsulated/adsorbed cisplatin. Animals receiving cisplatin, alone, developed neurotoxicity (inability to use the hind limbs). In pancreatic cancer xenografts, paclitaxel encapsulated into PLGA NPs, NDAT, alone, and NDAT bearing a payload of paclitaxel caused significant decreases in tumor weight. The greatest reduction in tumor weight (60%, P<0.01) was in animals exposed to NDAT bearing a drug payload and mean concentration of paclitaxel in these tumors (ng/gm tissue) exposed to an NDAT/paclitaxel payload was 5-fold more than in xenografts exposed to paclitaxel, alone, or paclitaxel encapsulated into PLGA NPs. Thus, the payload capacity of NDAT for cancer chemotherapeutic agents and tumor-specific delivery of cancer chemotherapeutic agents significantly increased bladder and pancreatic cancer content of, respectively, cisplatin and paclitaxel. Enhanced tumor size reduction and deceased systemic toxicity were achieved with this targeted approach.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Steroids & Hormonal Science.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Steroids & Hormonal Science
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Paul J Davis”
  • BylineArticles whose byline prints “Thangirala Sudha”
  • BylineArticles whose byline prints “Shaker A Mousa”